Bristol-Myers Halts Work on Diabetes Drug
- Share via
From the Associated Press
Bristol-Myers Squibb Co. said it halted development of a Type 2 diabetes drug because it would require an additional long-term study for approval and the company would rather focus its efforts on other products.
Last October, the Food and Drug Administration issued Bristol-Myers an approvable letter for Pargluva, known generically as muraglitazar, but requested more information on the drug’s cardiovascular safety before granting final approval.
